# Breakthrough for lethal pancreatic cancer: Drug combo 'makes tumours disappear'

> Drug combo for pancreatic cancer 'makes tumours disappear' in 1 in 12 patients, experts say.
- Title: Breakthrough for lethal pancreatic cancer: Drug combo 'makes…
- Summary: Drug combo for pancreatic cancer 'makes tumours disappear' in 1 in 12 patients, experts say.
- Keywords: pancreatic cancer, daraxonrasib, chemotherapy, tumor shrinkage, cancer treatment, clinical trial, mortality rate, cancer research, drug combination, Dailymail
- URL: https://shortify.news/Dailymail/breakthrough-for-lethal-pancreatic-cancer-drug-combo-makes-t
- Source: Dailymail — https://dailymail.com/health/article-16306023/pancreatic-cancer-breakthrough-drug-combo.html?ito=1490&ns_campaign=1490&ns_mchannel=rss
- Published: 2026-11-20T07:00:49+00:00
- Read time: 2 min
- Topics: pancreatic cancer, daraxonrasib, chemotherapy, tumor shrinkage, cancer treatment, clinical trial, mortality rate, cancer research, drug combination, news, entertainment
## Breakthrough for pancreatic cancer
Doctors hailed a breakthrough in fighting pancreatic cancer after a new drug combination showed tumors shrinking or disappearing in clinical trials.
## Drug combo shows promise
Daraxonrasib, when combined with chemotherapy, increased survival rates to 76.6% after one year compared to 45% with standard treatment alone.
## Tumors disappear in 1 in 12 patients
In 18 months, 1 in 12 patients saw their tumors completely disappear after treatment.
## Drug targets cancer growth
The drug locks onto the mutated KRAS gene, responsible for 90% of pancreatic tumors, to stop cancer cells from multiplying.
## Survival rates improve
Over 76% of patients survived one year after treatment, compared to 45% with standard care.
## Dr. Park's assessment
Dr. Wungki Park, an oncologist at Memorial Sloan Kettering, called the results the 'closest thing to a cure' for pancreatic cancer.

> This is the closest thing we've got to a cure. We have never seen so many patients whose cancer has spread respond completely to a drug.
## Pancreatic cancer statistics
11,500 people in the UK are diagnosed with pancreatic cancer yearly, with 10,200 dying from it.
## Treatment challenges
Fewer than 5% of patients discontinued treatment due to side effects like rash, diarrhea, fatigue, and nausea.
## Dr. Kara's call to action
Dr. Madina Kara urged the UK government to increase investment in pancreatic cancer research and fast-track new treatments.

> Half of people with pancreatic cancer die within three months of diagnosis and their loved ones would give anything to spend more precious time with them.
## Early symptoms of pancreatic cancer
Early warning signs include pain in the upper abdomen or back, unexplained weight loss, indigestion, and jaundice.
## Treatment limitations
Surgery is the only potential cure for advanced pancreatic cancer, but it's rarely possible by the time symptoms appear.
## Drug mechanism
Daraxonrasib works by targeting the mutated KRAS gene, which drives cancer growth in 90% of pancreatic tumors.
## Clinical trial results
In the trial, 60% of patients had tumors that shrank or disappeared, with 1 in 12 seeing complete tumor elimination.
## Survival statistics
76.6% of patients survived one year after treatment, compared to 45% with standard care.
## Drug approval history
US health officials approved Daraxonrasib in early 2026 after it doubled survival rates from 6.7 to 13.2 months.
## Cancer research impact
The findings offer hope for patients with advanced pancreatic cancer and highlight the need for more research funding.
## Key takeaway

Combination of Daraxonrasib and chemotherapy shrinks or erases pancreatic tumors in 60% of patients, with 1 in 12 seeing complete disappearance.

---

Summary: Shortify — https://shortify.news/Dailymail/breakthrough-for-lethal-pancreatic-cancer-drug-combo-makes-t
Reporting: Dailymail — https://dailymail.com/health/article-16306023/pancreatic-cancer-breakthrough-drug-combo.html?ito=1490&ns_campaign=1490&ns_mchannel=rss

When you use this summary, link the Shortify URL for the summary and credit the reporting to its newsroom.